Navigation Links
Pharmacyclics Announces Results of Registered Direct Offering
Date:6/17/2011

arbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations and beliefs regarding our future results or performance. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. Our actual results could differ materially from those projected in the forward-looking statements. Additionally, you should not consider past results to be an indication of our future performance. For a discussion of the risk factors and other factors that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.

About Pharmacyclics

Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Third Quarter 2011
2. Pharmacyclics Achieves $7 Million Development Milestone for HDAC Inhibitor, PCI-24781 / S 78454 with Servier
3. Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011
4. Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call
5. Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
6. Pharmacyclics, Inc. Rights Offering Oversubscribed
7. Pharmacyclics Announces Subscription Price for Rights Offering
8. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
9. Pharmacyclics Files Registration Statement for Rights Offering
10. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
11. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 In recent years, growing ... methods in product development and promotion has led to ... mistrust, fueled by concerns about the insidious impact of ... of spectacular fines to the world’s biggest pharmas for ...
(Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ...
(Date:1/14/2014)... USA, and Cardiff, UK (PRWEB) January 13, 2014 ... technology development leader with more than 20 years in ... for optics and photonics . Hainsey will serve as ... delighted to have Dr. Hainsey join SPIE as our ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed ... In this time period, doctors did not know that they ... the death of vulnerable patients. In the same way, medical ... be unwittingly transmitting herpes viruses to their patients. The CBCD ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... OSAKA, Japan, August 16 /PRNewswire-FirstCall/,-- Santhera Pharmaceuticals ... with a focus on neuromuscular diseases, and ... that the European Medicines Agency (EMEA) has ... (MAA) for Santhera,s lead compound,SNT-MC17 (INN: idebenone, ...
... Aug. 16 Cancer patients fraught with,flare-ups of ... assistance,in the form of a new easy-to-use oral ... quickly deliver pain medication. Cancer patients frequently ... cancer pain is characterized as continuous pain,present for ...
... 16 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... 2007 the,Nasdaq Listings Qualifications Department informed the Company ... below $50 million for 10,consecutive days, which is ... Market according to Marketplace Rule 4450(b)(1)(A). Nasdaq,also informed ...
Cached Biology Technology:European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 2European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 3European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 4European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 5European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 6Novel Technology Breaks Through Cancer Pain 2Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 2Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 3Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 4
(Date:4/17/2014)... developed at Sandia National Laboratories and recently licensed to ... cheaper. , Bacillus anthracis , the bacteria ... over the world and can cause serious, and often ... can survive in harsh conditions for decades. In humans, ... skin contact, inhalation of spores or eating contaminated meat. ...
(Date:4/17/2014)... about eight years ago, Katia Silvera , a postdoctoral ... were on a field trip in a mountainous area in ... never seen before. , Unable to identify it, they contacted ... turned out to be an unnamed species. So Carnevali recently ... "Lophiaris" is the genus name, comprising about 40 species in ...
(Date:4/17/2014)... a novel method to help kidney stone sufferers ... treatment possible., Kidney stones represent a major medical ... left untreated, apart from being particularly painful, they ... In many patients treated successfully, stone recurrence is ... approach to diagnosis and treatment needs to be ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3
... As researchers continue to examine the role ... people understand the differences among various ingredients used ... Association (CRA). Interchanging two distinctly different ingredients, such ... creates factually incorrect conclusions and misleads ,consumers. ...
... 4, 2009 Ben-Gurion University of the Negev engineers ... large nuclear reactors, making it unsuitable for use in ... form of the basic synthetic element found in commercial ... used for peaceful purposes. , This technique could help ...
... and very large reductions in greenhouse gas emissions compared ... messages from a series of expert papers on "The ... a special issue of Biofuels, Bioproducts and Biorefining ... which includes a comparative analysis of more than a ...
Cached Biology News:Pure fructose frequently confused with high fructose corn syrup 2Ben-Gurion University engineers develop technique to help combat nuclear proliferation 2Cellulosic biofuel technology will generate low-cost green fuel, says major study 2Cellulosic biofuel technology will generate low-cost green fuel, says major study 3
anti-dansyl, rabbit IgG fraction *1 mg/mL* Secondary Detection; Anti-Dye and Anti-Hapten Antibodies...
MOUSE ANTI GUINEA PIG T-CELLS (PAN):FITC Immunogen: Guinea pig peritoneal T-cells...
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
... cloning of BAC (100+kb), fosmid (40kb), and ... stability than any othe BAC vector. On ... yields and easy recombinant DNA purification. Available ... (pSMART VC) vectors for the highest insert ...
Biology Products: